Methods: Plasmapheresis and Protein A Immunoadsorption

Berntorp, Erik

doi:10.1002/9780470757260.ch5

Cited by 2 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secondly, the administration of aPCC and rVIIa is costly. It is enough to say sorption on columns using staphylococcal protein A (Thera-sorb®), which selectively binds the Fc fragment of human IgG, or through plasmapheresis [19,20]. The first method is not available in Poland.…”

Section: The Inhibitor Eliminationmentioning

confidence: 99%

Acquired haemophilia

Buczma¹,

Windyga²

2007

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

Acquired haemophilia (AH) is a severe bleeding diathesis that affects both males and females. It is caused by suddenly appearing autoantibodies that interfere with coagulation factor VIII (FVIII) activity. Although some conditions such as autoimmune diseases, cancer and puerperium seem likely to induce AH, in more than half of the observed cases autoantibodies to FVIII are idiopathic. The clinical picture is characterized by spontaneous and post-traumatic subcutaneous bleeds as well as massive mucosal membrane hemorrhages (from the genitourinary and gastrointestinal tracts). Typical abnormalities in AH are prolonged activated partial thromboplastin time and normal results of the other haemostatic tests (platelet count, prothrombin and thrombin times, fibrinogen concentration). Acquired haemophilia is definitely confirmed by quantification of FVIII neutralizing antibodies. Bleeds are usually treated with activated prothrombin complex concentrates and activated recombinant factor VII. In most patients with AH, the use of immunosupressive agents results in autoantibody elimination and restoration of normal FVIII plasma activity.

show abstract

Section: The Inhibitor Eliminationmentioning

confidence: 99%

Acquired haemophilia

Buczma¹,

Windyga²

2007

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

show abstract

“…In patients with very high titres, it is difficult to lower inhibitor levels close enough to zero to allow successful replacement therapy. A more efficient technique for inhibitor removal is extracorporeal adsorption to protein A or to columns using antihuman IgG (Ig‐TheraSorb® columns, Plasmaselect, Tetrow, Germany) [5].…”

Section: Extracorporeal Immunoadsorptionmentioning

confidence: 99%

Options for treating acute bleeds in addition to bypassing agents: extracorporeal immunoadsorption, FVIII/FIX, desmopressin and antifibrinolytics

Berntorp

2006

Haemophilia

Self Cite

View full text Add to dashboard Cite

Inhibitor patients do not always respond satisfactorily to treatment with bypassing agents, and options to the standard practice are sometimes needed. Temporary inhibitor removal may be achieved using extracorporeal immunoadsorption. This technique uses a column system including either protein A or antihuman IgG. Immunoadsorption may be used as part of an immune tolerance protocol, or in the case of acute bleeds or prior to surgery, thus rendering the patient more responsive to ordinary replacement therapy with factor VIII or factor IX. Desmopressin is a valuable haemostatic agent in many situations and can be especially recommended in mild haemophilia complicated by an inhibitor. Antifibrinolytics are often administered as an adjunct therapy to the treatment protocol and have also been reported to have a direct anti-inhibitor effect.

show abstract

Methods: Plasmapheresis and Protein A Immunoadsorption

Cited by 2 publications

References 27 publications

Acquired haemophilia

Acquired haemophilia

Options for treating acute bleeds in addition to bypassing agents: extracorporeal immunoadsorption, FVIII/FIX, desmopressin and antifibrinolytics

Contact Info

Product

Resources

About